Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
NCT07079423Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab in amyloid light chain amyloidosis, sponsored by Peking Union Medical College Hospital. Started Jun 2025; status: recruiting.
02
Drugs
teclistamab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT07079423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07079423.